Matteo Morotti
Overview
Explore the profile of Matteo Morotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spagnol G, Bigardi S, Zorzi M, Morotti M, Carollo M, Bruni G, et al.
J Clin Med
. 2024 Nov;
13(22).
PMID: 39598059
To analyze the role of PCI variation (Δ-PCI) before and after neoadjuvant chemotherapy (NACT) in an interval cytoreductive surgery (ICS) setting with the aim to propose a scoring model for...
2.
Ghisoni E, Morotti M, Sarivalasis A, Grimm A, Kandalaft L, Dangaj Laniti D, et al.
Nat Rev Clin Oncol
. 2024 Sep;
21(11):801-817.
PMID: 39232212
Despite documented evidence that ovarian cancer cells express immune-checkpoint molecules, such as PD-1 and PD-L1, and of a positive correlation between the presence of tumour-infiltrating lymphocytes and favourable overall survival...
3.
Spagnol G, Ghisoni E, Morotti M, Tommasi O, Marchetti M, Bigardi S, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000178
Immunotherapy, particularly the use of immune checkpoint inhibitors (ICIs), has shown limited efficacy in treating ovarian cancer (OC), possibly due to diverse T cell infiltration patterns in the tumor microenvironment....
4.
Morotti M, Grimm A, Hope H, Arnaud M, Desbuisson M, Rayroux N, et al.
Nature
. 2024 Apr;
629(8011):426-434.
PMID: 38658764
Expansion of antigen-experienced CD8 T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer. Interleukin-2 (IL-2) acts as a key regulator of...
5.
Lacher S, Dorr J, de Almeida G, Honninger J, Bayerl F, Hirschberger A, et al.
Nature
. 2024 Apr;
629(8011):417-425.
PMID: 38658748
Cancer-specific TCF1 stem-like CD8 T cells can drive protective anticancer immunity through expansion and effector cell differentiation; however, this response is dysfunctional in tumours. Current cancer immunotherapies can promote anticancer...
6.
Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, et al.
Sci Immunol
. 2024 Feb;
9(92):eadg7995.
PMID: 38306416
Adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples...
7.
Alsaadi A, Artibani M, Hu Z, Wietek N, Morotti M, Gonzalez L, et al.
Cell Rep
. 2023 Nov;
42(11):113354.
PMID: 37917586
The study of fallopian tube (FT) function in health and disease has been hampered by limited knowledge of FT stem cells and lack of in vitro models of stem cell...
8.
Ghisoni E, Morotti M, Colomer-Lahiguera S, Eicher M, Coukos G, Trueb L, et al.
J Immunother Cancer
. 2023 Jan;
10(12).
PMID: 36600604
Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized...
9.
Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong K, et al.
Oncogene
. 2022 Jun;
41(27):3584.
PMID: 35662285
No abstract available.
10.
Tantari M, Bogliolo S, Morotti M, Balaya V, Bouttitie F, Buenerd A, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008376
In patients with cervical cancer, the presence of tumoral lymph-vascular space invasion (LVSI) is the main risk factor for pelvic lymph node metastasis (PLNM). The objective of this study was...